A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates

Haemophilia

Volumn 11, Issue 1, 2005, Pages 5-12

  Lee, Martin L ^a   Roth, D A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bayesian; Factor VIII; Haemophilia A; Inhibitor risk

Indexed keywords

BISINACT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIGENICITY; BAYES THEOREM; CLINICAL RESEARCH; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG DESIGN; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXPERIMENTAL DESIGN; FOOD AND DRUG ADMINISTRATION; HEMOPHILIA A; HISTORY; HUMAN; INCIDENCE; LICENSING; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL MODEL;

BAYES THEOREM; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR V; HEMOPHILIA A; HUMANS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 13844276825     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01055.x     Document Type: Review

References (15)

1. Addiego JEJ, Gomperts E, Liu SL et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67: 19-27.
2. Peerlinck K, Arnout J, Di Giambattista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
3. Rosendaal FR, Nieuwenhuis HK, van der Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 2180-6.
4. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800-5.
5. White II, GC, Courter S, Bray GL, Lee M, Gomperts ED, the Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
6. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: results of a multicenter, international, clinical investigation. Thromb Haemost 2000; 83: 811-6.
7. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Sem Hematol 2001; 38(Suppl. 4): 44-51.
8. Food and Drug Administration Web site. Available at: http://www.fda.gov/cber/label/antibax072503LB.pdf. Accessed on January 9, 2004.
9. Ingerslev J. Workshop on factor VIII inhibitors held at the NIH, Bethesda, MD on 21 November 2003. Haemophilia 2004; 10: 288-9.
10. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48.
11. McMillan CW, Shapiro SS, Whitehurst D et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
12. Committee for Proprietary Medicinal Products (CPMP), EMEA. Note for guidance on the clinical investigation of recombinant factor VIII and IX products, 2000. http://www.emea.eu.int/pdfs/human/bpwg/156199en.pdf.
13. Casella G, Berger RL. Statistical Inference, 2nd edn. Pacific Grove, CA, USA: Duxbury Press, 2002: 324-5.
14. Berry D. Statistics: A Bayesian Perspective, 1st edn. Pacific Grove, CA, USA: Duxbury Press, 1995.
15. Spiegelhalter D, Abrams K, Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation, 1st edn. Indianapolis, IN, USA: John Wiley & Sons, 2004.